Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | EIF2AK2 | P19525 | 2/20 | 0.47 |
| ▸ | GBA1 | P04062 | 1/20 | 0.47 |
| ▸ | HTR1A | P08908 | 4/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 4/20 | 0.47 |
| ▸ | HTR7 | P34969 | 4/20 | 0.47 |
| ▸ | HTR6 | P50406 | 4/20 | 0.47 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.46 |
| ▸ | CDK2 | P24941 | 1/20 | 0.46 |
| ▸ | CDK9 | P50750 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1642383 | 0.88 | EIF2AK2 (0.55) | KMT2AMEN1EIF2AK2GBA1HTR1A | |
| SCHEMBL1641643 | 0.85 | HTT (0.49) | KMT2AMEN1EIF2AK2GBA1HTR1A | |
| SCHEMBL1642371 | 0.84 | GBA1 (0.63) | KMT2AMEN1EIF2AK2GBA1HTR1A | |
| SCHEMBL1641373 | 0.80 | PDPK1 (0.53) | KMT2AMEN1GBA1NPC1RAB9A | |
| SCHEMBL1642875 | 0.79 | KMT2A (0.54) | KMT2AMEN1GBA1HTR1ADRD2 | |
| SCHEMBL1642612 | 0.77 | CYP1A2 (0.55) | KMT2AMEN1CDK2SMN1; SMN2LMNA | |
| SCHEMBL20557614 | 0.70 | EIF2AK2 (0.61) | KMT2AMEN1EIF2AK2GBA1HTR1A | |
| SCHEMBL4900043 | 0.69 | EIF2AK2 (0.75) | KMT2AMEN1EIF2AK2GBA1HTR1A | |
| SCHEMBL23991684 | 0.69 | GBA1 (0.41) | KMT2AMEN1EIF2AK2GBA1NPC1 | |
| SCHEMBL31240605 | 0.69 | AKT1 (0.50) | KMT2AMEN1EIF2AK2HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2671876-A2 | Pyrazine derivatives and their use as protein kinase inhbitors | Akinion Pharmaceuticals AB (SE) | 2013-12-11 | — | — | EP | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | AKINION PHARMACEUTICALS AB (SE) | 2013-08-08 | — | — | US | disclosed |
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
| WO-2009095399-A2 | PYRAZINE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHBITORS | AKINION PHARMACEUTICALS AB (SE) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130203774-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | KMT2A 114/4885MEN1 359/4885EIF2AK2 3543/4885 |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | KMT2A 114/4885MEN1 359/4885EIF2AK2 3543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.